Abstract:Abstract Based on previous models, among individuals who are not known to carry a pathogenic variant, lifetime risk of ovarian cancer ranges between ~0.1% and ~11%. Risk stratification to identify the people at the higher end of this lifetime risk range is of paramount importance for prevention efforts. Previous risk stratification models for ovarian cancer were based on a limited number of risk/protective factors. Further, we have also shown that risk estimates differ by menopausal status which most models have not considered. We aimed to develop and internally validate a risk stratification model for ovarian cancer that considers 15 unequivocal risk/protective factors and properly accounts for effect modification by menopausal status. We used data from nine studies (7,984 cases, 12,260 controls) participating in the Ovarian Cancer Association Consortium (OCAC). The data were split into a training set and a test set that comprised 80% and 20% of the OCAC dataset, respectively. Seven risk factors (body mass index, height, later age at menopause, menopausal hormonal therapy use, first-degree family history of ovarian cancer, endometriosis, and a polygenic score of 36 common genetic variants) and eight protective factors (later age at menarche, parity, breastfeeding, incomplete pregnancy, later age at last pregnancy, tubal ligation, combined oral contraceptive use and depot-medroxyprogesterone acetate use) were included. Other risk/protective factors such as talcum powder or aspirin use were not included due to high proportions of missing values. We fit multiplicative logistic regression models separately by menopausal status group in the training set to determine the associations between the factors and ovarian cancer. All models were adjusted for race/ethnicity, education level, age and OCAC study. In the test set, we calculated a summary relative risk for every combination of the 15 risk/protective factors (hereafter called a risk profile) based on the estimates from the training set. The summary relative risk was then translated into an absolute risk: the frequency-weighted average of all the profile-specific relative risks was scaled to the average absolute risk, and then this scaling factor was applied to each profile-specific relative risk and its confidence interval (CI). The range of absolute lifetime risks observed in the test set was 0.1%-7.2% using 15 factors, accounting for menopausal status. The area under the receiving operating curve (AUC) was 0.67 (95% CI 0.65-0.68). This is slightly higher than the previous risk stratification models (AUC=0.55-0.66). External validation of our risk stratification model in a longitudinal cohort is warranted, as our findings suggest that there is a subset of individuals at the higher end of the risk range who would be potential candidates for primary prevention strategies including salpingectomy. Citation Format: Minh Tung Phung, Alice W. Lee, Karen McLean, Lilah Khoja, Hoda Anton-Culver, Elisa V. Bandera, Jennifer Anne Doherty, Renee T. Fortner, Marc T. Goodman, Francesmary Modugno, Paul D. P. Pharoah, Kathryn L. Terry, Penelope M. Webb, Anna H. Wu, Andrew Berchuck, Gillian E. Hanley, Bhramar Mukherjee, Malcolm C. Pike, Celeste Leigh Pearce, Britton Trabert. Development and validation of an improved risk stratification model for ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2):Abstract nr B047.

Risk prediction models for endometrial cancer: development and validation in an international consortium

Candidate Locus Analysis of the TERT – CLPTM1L Cancer Risk Region on Chromosome 5p15 Identifies Multiple Independent Variants Associated with Endometrial Cancer Risk

An epidemiological model for prediction of endometrial cancer risk in Europe

Development of a Breast Cancer Risk Prediction Model Integrating Monogenic, Polygenic, and Epidemiologic Risk

Understanding risk factors for endometrial cancer in young women

Predicting risk of endometrial cancer in asymptomatic women (PRECISION): Model development and external validation

Fine-mapping of the HNF1B Multicancer Locus Identifies Candidate Variants That Mediate Endometrial Cancer Risk.

Abstract B052: Ovarian cancer risk prediction: a systematic assessment of the state of the art and development of a new model

Development and Validation of a Novel Prognostic Model for Endometrial Cancer Based on Clinical Characteristics

Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers.

Abstract B047: Development and validation of an improved risk stratification model for ovarian cancer

Model Predicting the Risk of Endometrial Hyperplasia Developing into Endometrial Cancer

Ovarian Cancer Risk Prediction - a Clinical Epidemiology Perspective

Supplementary Table S5 from Development of a Breast Cancer Risk Prediction Model Integrating Monogenic, Polygenic, and Epidemiologic Risk

Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case–control study

Predictive models for lymph node metastasis in endometrial cancer: A systematic review and bibliometric analysis

Supplementary Table S4 from Development of a Breast Cancer Risk Prediction Model Integrating Monogenic, Polygenic, and Epidemiologic Risk

Integration of Genomic and Clinical Retrospective Data to Predict Endometrioid Endometrial Cancer Recurrence

Risk Prediction Model for Epithelial Ovarian Cancer Using Molecular Markers and Clinical Characteristics

Circulating inflammatory and immune response proteins and endometrial cancer risk: a nested case-control study and Mendelian randomization analyses

Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers